<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287078</url>
  </required_header>
  <id_info>
    <org_study_id>110068</org_study_id>
    <secondary_id>11-H-0068</secondary_id>
    <nct_id>NCT01287078</nct_id>
  </id_info>
  <brief_title>Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome</brief_title>
  <official_title>Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Bronchiolitis obliterans or bronchiolitis obliterans syndrome is a lung disorder that&#xD;
      occurs as a complication of either lung transplantation or bone marrow/blood stem cell&#xD;
      transplantation. One of the complications of transplant is the occurrence of graft versus&#xD;
      host disease (in hematopoietic stem cell transplants) and host versus graft disease (in lung&#xD;
      transplantation). In these diseases, the cells attack the lungs and cause irreversible small&#xD;
      airway fibrosis referred to as bronchiolitis obliterans syndrome. When a patient develops&#xD;
      fibrosis of the lungs or bronchioles, the lungs no longer work properly, which causes&#xD;
      difficulties with breathing that lead to a diminished quality of life and an increased risk&#xD;
      of death. Treatment typically involves immunosuppressive therapy such as oral cyclosporine or&#xD;
      steroid therapy, but these treatments are only marginally effective and can cause significant&#xD;
      toxicities and increase the risk of infections. Inhaled cyclosporine (CIS) achieves higher&#xD;
      concentrations of cyclosporine in the lungs and lower concentrations of cyclosporine in the&#xD;
      blood than oral cyclosporine. Therefore, it could have advantages over conventional oral&#xD;
      immunosuppressive therapies used to treat this disorder. Researchers are interested in&#xD;
      testing whether inhaled cyclosporine therapy could be used as a safe and effective treatment&#xD;
      for bronchiolitis obliterans or bronchiolitis obliterans syndrome occurring after bone&#xD;
      marrow/blood stem cell or lung transplants.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate whether inhaled cyclosporine (CIS) can improve or stabilize lung function and&#xD;
      quality of life in individuals with bronchiolitis obliterans.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals between 10 and 80 years of age who have been diagnosed with bronchiolitis&#xD;
      obliterans or bronchiolitis obliterans syndrome after blood or lung transplants.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a full medical history and physical examination, as&#xD;
           well as blood and urine tests, lung function tests, imaging studies, bronchoalveolar&#xD;
           lavage samples, and quality of life questionnaires.&#xD;
&#xD;
        -  Participants will take cyclosporine inhalation solution through a nebulizer. The&#xD;
           nebulizer generates a mist of cyclosporine inhalation solution (CIS), which is then&#xD;
           breathed in through a mouthpiece. The process takes approximately 20 minutes. The&#xD;
           solution will be provided in single-use vials.&#xD;
&#xD;
        -  Participants will continue to take all medications for post-transplant care as required&#xD;
           by their doctor and the study researchers. Attempts will be made to reduce the doses and&#xD;
           types of immunosuppressants given to participants on the study, as long as the treatment&#xD;
           continues to produce improved or stable lung function.&#xD;
&#xD;
        -  Participants will have study visits every 3 weeks with blood and urine tests, lung&#xD;
           function tests, and imaging studies. Participants will undergo repeat bronchoalveolar&#xD;
           sample at week 9 and 18. Participants will also complete quality of life questionnaires&#xD;
           as directed. Treatment will continue for a minimum of 18 weeks, followed by a final&#xD;
           follow-up visit 2 weeks after the end of the study.&#xD;
&#xD;
        -  Participants who benefit from the inhaled cyclosporine (CIS) may continue to receive&#xD;
           further therapy with inhaled cyclosporine at the end of the study by participation in a&#xD;
           separate study extension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiolitis Obliterans (BO) is an obstructive lung disease that can affect individuals that&#xD;
      have undergone a lung or hematopoietic stem cell transplant. BO has been studied most&#xD;
      extensively in lung transplant recipients, where it is considered to represent chronic lung&#xD;
      rejection. It is the leading cause of death after lung transplant, with mortality rates up to&#xD;
      55%. In hematopoietic stem cell transplantation, BO is thought to be a manifestation of&#xD;
      chronic graft-vs-host disease (GVHD). Up to 45% of patients undergoing hematopoietic stem&#xD;
      cell transplantation at the NHLBI develop a decline in pulmonary function. Conventional&#xD;
      therapy for patients who develop BO consists of augmentation of systemic immunosuppressants.&#xD;
      Systemic immunosuppression has limited efficacy for BO and is associated with deleterious&#xD;
      consequences including increased risk of infections and decreased graft-versus tumor/leukemia&#xD;
      effects.&#xD;
&#xD;
      Recently, cyclosporine inhalation solution (CIS) in solution with propylene glycol has been&#xD;
      shown to improve overall survival and chronic rejection-free survival in lung transplant&#xD;
      patients. These findings suggest targeted delivery of immunosuppressive therapy to the&#xD;
      diseased organ warrants further investigation as this may minimize the morbidity associated&#xD;
      with systemic immunosuppression. However, there currently exists limited data regarding the&#xD;
      overall efficacy of inhaled cyclosporine to treat established BO following lung&#xD;
      transplantation. Furthermore, inhaled cyclosporine has not been studied in the treatment of&#xD;
      BO following hematopoietic stem cell transplantation.&#xD;
&#xD;
      Here, we propose to evaluate the safety, efficacy, and pharmacodynamics of inhaled&#xD;
      cyclosporine for the treatment of BO. Two distinct patient populations will be offered&#xD;
      enrollment in this protocol: hematopoietic transplant recipients with BO (group A) and lung&#xD;
      transplant recipients with BO (group B). Study participants will receive CIS at an initial&#xD;
      dose of 150mg, three times weekly. Patients will undergo dose titration to a maximum dose of&#xD;
      300mg, three times weekly. Drug deposition and pharmacokinetic analyses will be performed at&#xD;
      the initiation of treatment. Clinical parameters, including pulmonary function tests, will be&#xD;
      measured in addition to laboratory markers of the anti-inflammatory response to CIS. Adverse&#xD;
      events associated with treatment will be recorded.&#xD;
&#xD;
      The primary objective is to 1) assess the safety and efficacy of inhaled cyclosporine as a&#xD;
      new therapy in hematopoietic transplant patients and lung transplant patients with&#xD;
      established BO. Additionally, we seek to promote a better understanding of the pathogenesis&#xD;
      of BO in these two transplant groups and to assess the anti-inflammatory effects of inhaled&#xD;
      cyclosporine in patients that develop this complication.&#xD;
&#xD;
      The primary endpoint of each study group is the best response, FEV1 improvement or&#xD;
      stabilization from study baseline at week 18 for two successive measures, at least 1 week&#xD;
      apart, no more than 2 weeks apart. Secondary endpoints include the toxicity profile as&#xD;
      measured by CTCAE criteria (safety), the study of pharmacokinetics and lung deposition&#xD;
      characteristics of inhaled cyclosporine, improvement in high resolution chest CT images,&#xD;
      results of peripheral blood and bronchoalveolar cytokine arrays to assess secondary markers&#xD;
      of inflammation, and functional capacity measurements using a six-minute walk test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 29, 2011</start_date>
  <completion_date type="Actual">August 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 8, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants who responded to treatment with cyclosporine inhalation solution (CIS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Non-response to Treatment</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants who did not respond to treatment with cyclosporine inhalation solution (CIS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable or Progressive Disease at Baseline With Improvement of FEV1</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants with stable or progressive disease at baseline with improvement of FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Progression at Baseline With Stablization of FEV1</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants with progressive disease at baseline with stablization of FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Stability at Baseline With Stablization in FEV1 and Greater Than 25% Decline in Systemic Immunosuppression</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable or Progressive Disease at Baseline With Greater Than 20% of Decline in FEV1</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable Disease at Baseline With Stablization of FEV1 and no Change or Increase in Systemic Immunosuppresion</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Progression at Baseline With Decline in FEV1 Greater Than 10%</measure>
    <time_frame>18 weeks</time_frame>
    <description>Participants with progressive disease at baseline with decline in FEV1 greater than 10%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Constrictive Bronchiolitis</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Graft vs Host Disease</condition>
  <condition>Bronchiolitis, Exudative</condition>
  <condition>Bronchiolitis, Proliferative</condition>
  <arm_group>
    <arm_group_label>Inhaled Cyclosporine in Lung Transplant and HSCT Recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Inhalation Solution</intervention_name>
    <description>sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.</description>
    <arm_group_label>Inhaled Cyclosporine in Lung Transplant and HSCT Recipients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        History of:&lt;TAB&gt;&#xD;
&#xD;
        -Hematopoietic stem cell transplant recipients at least 99 days post transplant (group A)&#xD;
&#xD;
        Or&#xD;
&#xD;
          -  Lung transplant recipients at least 6 months post transplant (Group B)&#xD;
&#xD;
          -  Biopsy proven bronchiolitis obliterans (confirmed by NIH pathology department) or&#xD;
             Bronchiolitis Obliterans Syndrome (BOS) as defined by:&#xD;
&#xD;
          -  FEV1 less than 75 percent predicted and&#xD;
&#xD;
          -  No evidence of pulmonary infection as a causative etiology to lung dysfunction or&#xD;
             other causative etiology&#xD;
&#xD;
          -  Decline in FEV1 (The FEV1 values used to determine BOS will be the average of 2&#xD;
             measurements of FEV1 taken sequentially at least 3 weeks apart up to 6 months apart)&#xD;
             compared to pre-transplant baseline for group A or compared to best post-transplant&#xD;
             measurement in group B.&#xD;
&#xD;
          -  For hematopoietic transplant patients, FEV1 must have declined less than 10 percent&#xD;
             from pre-transplant baseline (group A)&#xD;
&#xD;
          -  For lung transplant patients, FEV1 must have declined greater than 20 percent from&#xD;
             best post-transplant measurement (group B)&#xD;
&#xD;
        And one of the following:&#xD;
&#xD;
          -  FEV1/FVC less than 0.7&#xD;
&#xD;
          -  Air trapping seen on CT scan or RV greater than 20 percent predicted&#xD;
&#xD;
          -  Evidence of cGVHD affecting at least one other organ system (group A)&#xD;
&#xD;
          -  Age 10-80 years&#xD;
&#xD;
          -  Progressive disease or stable disease (active BOS, stable by FEV1 criteria) on&#xD;
             immunosuppressants at study entry&#xD;
&#xD;
          -  Progressive disease at study entry: Diagnosis of BO or BOS with evidence of a&#xD;
             progressive decline in FEV1. A documented decline (greater than or equal 10 percent)&#xD;
             in FEV1 has occurred within 18 weeks (minimum documentation of 3 weeks) preceding&#xD;
             study enrollment&#xD;
&#xD;
          -  Stable disease at study entry: Diagnosis of BO or BOS on immunosuppressive therapy&#xD;
             with evidence of stable disease (active BOS, stable by FEV1 criteria), as documented&#xD;
             by a stable FEV1 (increase &lt;5% and decrease &lt;10%) within 18 weeks (minimum&#xD;
             documentation of 3 weeks) preceding study enrollment&#xD;
&#xD;
          -  Patients on calcineurin inhibitors at study entry will be required to be on a stable&#xD;
             dose of the calcineurin inhibitor for 4 weeks prior to study enrollment&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Evidence of uncontrolled, pulmonary infection&#xD;
&#xD;
          -  Patients with unstable coronary insufficiency, severe cardiac arrhythmias, and/or&#xD;
             uncontrolled hypertension.&#xD;
&#xD;
          -  History of hypersensitivity to propylene glycol&#xD;
&#xD;
          -  History of allergic reaction or hypersensitivity to Technetium- 99m sulfur colloid,&#xD;
             used in lung deposition studies&#xD;
&#xD;
          -  ECOG performance status greater than or equal to 3&#xD;
&#xD;
          -  Serum creatinine &gt;2.5 mg/dl&#xD;
&#xD;
          -  Documented allergy or intolerance to cyclosporine&#xD;
&#xD;
          -  Patient pregnant or breast feeding or not willing to use an approved method of birth&#xD;
             control&#xD;
&#xD;
          -  Inability to comprehend the investigational nature of the study and provide informed&#xD;
             consent&#xD;
&#xD;
          -  Life expectancy less than 18 weeks.&#xD;
&#xD;
          -  An increase greater than or equal to 5% and an absolute increase greater than or equal&#xD;
             to 0.05 in FEV1 in the 18 weeks (minimum documentation of 3 weeks) preceding study&#xD;
             enrollment&#xD;
&#xD;
          -  Subjects who have had prior administration of inhaled cyclosporine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole J Gormley, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-H-0068.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 Sep;28(5):425-34. Review.</citation>
    <PMID>11593314</PMID>
  </reference>
  <reference>
    <citation>Boucek MM, Waltz DA, Edwards LB, Taylor DO, Keck BM, Trulock EP, Hertz MI; International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report--2006. J Heart Lung Transplant. 2006 Aug;25(8):893-903.</citation>
    <PMID>16890109</PMID>
  </reference>
  <reference>
    <citation>Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, Rezvani K, Karimpour S, Childs R, Barrett AJ. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant. 2006 Dec;12(12):1261-9.</citation>
    <PMID>17162207</PMID>
  </reference>
  <verification_date>August 31, 2018</verification_date>
  <study_first_submitted>January 29, 2011</study_first_submitted>
  <study_first_submitted_qc>January 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <results_first_submitted>August 3, 2020</results_first_submitted>
  <results_first_submitted_qc>September 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2020</results_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Blood Stem Cell Transplant</keyword>
  <keyword>Inhaled Cyclosporine</keyword>
  <keyword>Graft-Versus-Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Bronchiolitis Obliterans</keyword>
  <keyword>Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT01287078/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects withdrew consent after signing</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Cyclosporine in HSCT Recipients</title>
          <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
        </group>
        <group group_id="P2">
          <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
          <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Cyclosporine in HSCT Recipients</title>
          <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
        </group>
        <group group_id="B2">
          <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
          <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS)</title>
        <description>Participants who responded to treatment with cyclosporine inhalation solution (CIS)</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS)</title>
          <description>Participants who responded to treatment with cyclosporine inhalation solution (CIS)</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Non-response to Treatment</title>
        <description>Participants who did not respond to treatment with cyclosporine inhalation solution (CIS)</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Non-response to Treatment</title>
          <description>Participants who did not respond to treatment with cyclosporine inhalation solution (CIS)</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stable or Progressive Disease at Baseline With Improvement of FEV1</title>
        <description>Participants with stable or progressive disease at baseline with improvement of FEV1</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Stable or Progressive Disease at Baseline With Improvement of FEV1</title>
          <description>Participants with stable or progressive disease at baseline with improvement of FEV1</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Progression at Baseline With Stablization of FEV1</title>
        <description>Participants with progressive disease at baseline with stablization of FEV1</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression at Baseline With Stablization of FEV1</title>
          <description>Participants with progressive disease at baseline with stablization of FEV1</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Stability at Baseline With Stablization in FEV1 and Greater Than 25% Decline in Systemic Immunosuppression</title>
        <description>Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Stability at Baseline With Stablization in FEV1 and Greater Than 25% Decline in Systemic Immunosuppression</title>
          <description>Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stable or Progressive Disease at Baseline With Greater Than 20% of Decline in FEV1</title>
        <description>Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Stable or Progressive Disease at Baseline With Greater Than 20% of Decline in FEV1</title>
          <description>Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stable Disease at Baseline With Stablization of FEV1 and no Change or Increase in Systemic Immunosuppresion</title>
        <description>Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Stable Disease at Baseline With Stablization of FEV1 and no Change or Increase in Systemic Immunosuppresion</title>
          <description>Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Progression at Baseline With Decline in FEV1 Greater Than 10%</title>
        <description>Participants with progressive disease at baseline with decline in FEV1 greater than 10%</description>
        <time_frame>18 weeks</time_frame>
        <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Cyclosporine in HSCT Recipients</title>
            <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
          <group group_id="O2">
            <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
            <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression at Baseline With Decline in FEV1 Greater Than 10%</title>
          <description>Participants with progressive disease at baseline with decline in FEV1 greater than 10%</description>
          <population>Subjects who received cyclosporine inhalation solution (CIS) for at least two weeks or three doses</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Cyclosporine in HSCT Recipients</title>
          <description>Subjects who underwent Hematopoietic Stem Cell Transplant (HSCT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
        </group>
        <group group_id="E2">
          <title>Inhaled Cyclosporine in Lung Transplant Recipients</title>
          <description>Subjects who underwent Lung Transplant (LT) and developed Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mycobacterium abscessus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vocal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Richard Childs</name_or_title>
      <organization>National Heart Lung and Blood Institute</organization>
      <phone>301-451-7128</phone>
      <email>childsr@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

